权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Validating Quantitative Magnetic Resonance Imaging Biomarkers of Idiopathic Pulmonary Fibrosis

验证特发性肺纤维化的定量磁共振成像生物标志物

基本信息

批准号：
10528488
负责人：
ZACKARY I CLEVELAND
金额：
$ 74.37万
依托单位：
CINCINNATI CHILDRENS HOSP MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-01-01 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10528488
关键词：
3-Dimensional Acute Age Alveolar Animal Model Animals Biological Biomechanics Biophysics Biopsy Cell Proliferation Chemicals Cicatrix Clinical Collagen Consensus Data Deposition Development Diagnosis Diffuse Diffusion Disease Progression Disease model Early Diagnosis Elements Environmental Exposure Epithelium Etiology Event Exhibits Extracellular Matrix FDA approved Failure Fibrosis Functional disorder Gases Goals Growth Health Health Care Costs Human Image Imaging technology Impairment Inflammation Inflammatory Injury Interstitial Lung Diseases Knowledge Lesion Life Link Lung Lung Compliance Lung diseases Magnetic Resonance Imaging Measures Mechanical Stress Mechanical ventilation Mechanics Mediator Methods Microscopic Mission Modeling Molecular Monitor Morbidity - disease rate Mus Outcome Pathologic Pathology Patients Persons Pharmaceutical Preparations Physiology Pirfenidone Predisposition Process Profibrotic signal Property Public Health Pulmonary Fibrosis Pulmonary Pathology Pulmonary Surfactant-Associated Protein A Pulmonary Surfactant-Associated Protein C Radiation Relaxation Research Resolution Signal Transduction Structure Structure of parenchyma of lung Surface Technology Testing Time Tissues Transgenic Mice Transgenic Organisms Translating Treatment Efficacy United States National Institutes of Health Ventilator Water Work X-Ray Computed Tomography clinical diagnosis clinical translation density fibrotic lung functional decline idiopathic pulmonary fibrosis image processing image reconstruction imaging biomarker in vivo injured innovation insight lung imaging magnetic resonance imaging biomarker mortality mouse model mutant nintedanib normal aging novel strategies novel therapeutics overexpression pre-clinical preclinical study pulmonary function pulmonary function decline reconstruction temporal measurement therapeutic target therapeutically effective therapy development tool treatment response ventilation

项目摘要

Pulmonary fibrosis contributes to morbidity and mortality in a wide spectrum of lung diseases. While it can result from environmental exposures or acute injuries, the events that initiate lung fibrosis are typically unknown. This Idiopathic Pulmonary Fibrosis (IPF) is the most common form of interstitial lung disease, and it is associated with a post-diagnosis survival of only 3 years. Despite decades of research, only 2 drugs are FDA approved to treat IPF, and both merely slow its progression. Failure to produce treatments to reverse or halt disease progression can be attributed to poorly understood IPF etiology. In turn, poor understanding can be attributed to an inability to detect and quantify early fibrosis and relate regional parenchymal remodeling to the functional, biomechanical, and molecular processes that initiate fibrosis. Eliminating this gap will require significant scientific and technical developments involving both biologically realistic disease models and sensitive and specific imaging technology. The long-term goal of this research is to quantify early pulmonary remodeling and relate it to profibrotic mecha- nisms and emergent pathophysiology. Our objectives in this application are to 1) determine the biophysical origin of magnetic resonance imaging (MRI) relaxation in fibrotic lung tissue, 2) quantify alveolar ventilation, 3) apply these metrics to two realistic, transgenic mouse models, and 4) extend quantitative ventilation MRI to IPF pa- tients. Our central hypothesis is that relaxation and ventilation will correlate with ex vivo measures of fibrosis (e.g., regional collagen content) and provide sensitive, noninvasive methods of quantifying fibrosis progression in vivo. Our rationale is that imaging markers—once validated in animal models and IPF patients—can readily be applied in mechanistic preclinical studies and in assessing IPF progression and therapy efficacy. Guided by strong preliminary data and theoretical work describing MR signal dynamics in the lungs, our central hypothesis will be tested by completing the following three Specific Aims: 1) validate transverse relaxation as a marker of lung fibrosis; 2) quantify impaired ventilation with multi-breath HP 129Xe washout; and 3) demonstrate the sensi- tivity of HP 129Xe washout MRI to impaired ventilation in IPF patients. Under Aim 1, we have developed the MRI sequences and reconstruction pipeline needed to complete the work. Under Aim 2, we have constructed and validated a hyperpolarized gas and MRI-compatible ventilator and developed the image processing tools to quantify regional tissue density. Under Aim 3, we have pioneered the use of efficient 3D spiral MRI sequences and keyhole-based image reconstruction to produce high-quality, quantitative human lung images. The proposed research is innovative both biologically and technically, because it will develop and validate noninvasive, regional measures of biophysical tissue properties and ventilation. These results are significant, because they will provide a means of detecting early pro-fibrotic events and noninvasively quantifying lung fibrosis progression. This work will have an immediate positive impact by allowing potential lung fibrosis therapies to be assessed and will pro- vide tools that can be translated into clinical use for evaluating disease progression and therapy response.

肺纤维化导致多种肺部疾病的发病率和死亡率。虽然这可能导致由于环境暴露或急性损伤，引发肺纤维化的事件通常是未知的。这特发性肺纤维化（IPF）是间质性肺病的最常见形式，并且其与诊断后生存期仅为3年。尽管经过数十年的研究，只有两种药物被FDA批准用于治疗 IPF，两者都只是减缓其进展。未能产生逆转或阻止疾病进展的治疗方法可归因于对IPF病因知之甚少。反过来，理解力差可以归因于为了检测和量化早期纤维化，并将局部实质重塑与功能，生物力学，以及引发纤维化的分子过程。消除这一差距将需要大量的科学和技术发展涉及生物学上真实的疾病模型和敏感和特定的成像技术。这项研究的长期目标是量化早期肺重塑，并将其与促纤维化机制联系起来。 nisms和紧急病理生理学。我们在本申请中的目标是1）确定生物物理起源的磁共振成像（MRI）松弛纤维化肺组织，2）量化肺泡通气，3）应用将这些指标应用于两种真实的转基因小鼠模型，以及4）将定量通气MRI扩展到IPF患者， tients。我们的中心假设是松弛和通气将与纤维化的离体测量相关 (e.g.,局部胶原含量），并提供了定量纤维化进展的灵敏、非侵入性方法 in vivo.我们的基本原理是，一旦在动物模型和IPF患者中得到验证，用于机制临床前研究和评估IPF进展和治疗疗效。指导强有力的初步数据和理论工作描述了肺部的MR信号动力学，我们的中心假设将通过完成以下三个具体目标进行测试：1）验证横向松弛作为肺纤维化; 2）用多次呼吸HP 129洗脱定量通气受损; 3）证明敏感性， HP 129 Xe冲洗MRI对IPF患者通气受损的影响。在目标1下，我们开发了MRI 序列和重建管道需要完成的工作。在目标2下，我们构建了验证了超极化气体和MRI兼容的呼吸机，并开发了图像处理工具，量化局部组织密度。根据目标3，我们率先使用高效的3D螺旋MRI序列以及基于锁孔的图像重建，以产生高质量的定量人类肺部图像。拟议研究在生物学和技术上都是创新的，因为它将开发和验证非侵入性的，区域性的，生物物理组织特性和通气的测量。这些结果意义重大，因为它们将提供一种检测早期促纤维化事件和非侵入性定量肺纤维化进展的方法。这项工作将通过评估潜在的肺纤维化治疗产生直接的积极影响，并将促进这些工具可以转化为临床应用，用于评估疾病进展和治疗反应。